How Bladder Cancer ctDNA Testing is Changing the Treatment Process
-
Explore Bladder Cancer
- Overview
- Grades & Staging
After finishing treatment for muscle-invasive bladder cancer (MIBC), you might be concerned about whether any cancer cells remain in your body, even if imaging shows no signs of disease. A newer blood test called circulating tumor DNA (ctDNA) testing can offer additional insights into your risk of recurrence following surgery.
Recently, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing for certain people who have undergone bladder removal surgery, called a radical cystectomy. This is a significant update to the surgical follow-up process for bladder cancer patients, allowing ctDNA results to guide whether additional treatments are necessary.
What is ctDNA Testing?
Circulating tumor DNA (ctDNA) refers to tiny pieces of DNA that cancer cells release into the bloodstream. A ctDNA test detects DNA that is associated with a specific tumor in a patient.
One advantage of ctDNA testing is that it can sometimes identify cancer before it becomes large enough to be visible on imaging scans, making it a valuable tool for monitoring and managing cancer. In bladder cancer, a ctDNA test uses data from a patient’s tumor to search for signs of cancer that may still exist at a molecular level.
It’s important to note that ctDNA testing differs from genetic testing, which assesses whether you have inherited genetic changes that increase your risk of developing cancer. Instead, ctDNA looks for evidence of DNA originating from the cancer itself. The ctDNA test is also different from tumor marker tests, which have been used for many years to indicate whether proteins associated with specific types of cancer are present in the patient’s bloodstream.
What Is Molecular Residual Disease?
Molecular residual disease (MRD) refers to very small amounts of cancer that may remain in the body after treatment but are undetectable through standard imaging or routine blood tests.
For example, after radical cystectomy, scans may show no visible cancer, even though microscopic cancer cells may still be present. If these cells remain and start to grow, they can eventually lead to a recurrence of bladder cancer.
ctDNA testing is one method that doctors can use to find molecular evidence of this MRD. Detecting ctDNA after treatment may suggest a higher risk of bladder cancer returning.
New NCCN Guidelines for ctDNA Testing in Bladder Cancer
The updated NCCN guidelines represent a significant development in the use of blood-based testing for muscle-invasive bladder cancer. The NCCN recommends considering ctDNA-MRD testing as a tool for risk assessment and to help determine whether adjuvant immunotherapy should be used after cystectomy in appropriate patients who have not previously received an immune checkpoint inhibitor. The updated guidance focuses on a personalized, tumor-informed multiplex PCR-next-generation sequencing analysis for ctDNA.
For eligible patients who receive a positive ctDNA-MRD result within one year of cystectomy, the new recommendations include treatment with an immunotherapy called atezolizumab (Tecentriq), based on clinical trial evidence. Instead of directly killing cancer cells, this drug works by helping the body's own immune system find and destroy them.
Who Is a Candidate for ctDNA Testing?
The new recommendation is focused on people with muscle-invasive bladder cancer who have undergone radical cystectomy and have not previously received immune checkpoint inhibitor therapy. This means that earlier-stage, non-muscle invasive bladder cancer patients are not likely to have this as part of their follow-up testing.
Your oncologist will determine whether ctDNA is appropriate for you. This decision may depend on several factors, including:
- The type and stage of your bladder cancer
- Whether you have undergone a radical cystectomy
- The findings from your surgery and pathology
- Treatments you received before surgery
- Whether you previously received immunotherapy
- Your overall health and individual treatment goals
Not everyone with bladder cancer will need ctDNA testing. Your RMCC oncologist can explain whether testing may provide useful information in your particular situation.
How Does ctDNA Testing Work?
ctDNA testing generally involves several steps:
- The tumor is analyzed to identify characteristics that can be used to look for tumor-specific DNA in your blood.
- A sample is collected through a standard blood draw.
- The lab examines the sample for DNA associated with the tumor.
- The test report will indicate whether ctDNA was detected in the blood sample.
- Testing may be repeated over time to monitor for molecular residual disease.
What Does a Positive ctDNA Test Mean?
A positive ctDNA result means tumor-associated DNA was found in your blood sample. After cystectomy, this may indicate molecular residual disease and a higher risk of bladder cancer returning.
It’s important to understand that a positive result does not necessarily mean that a tumor or metastatic cancer can currently be seen on an imaging scan. ctDNA testing may detect molecular evidence of cancer before there is visible evidence of disease.
Under the new NCCN recommendations, eligible patients who become ctDNA-MRD-positive within one year following cystectomy may be candidates for adjuvant atezolizumab. The decision to use immunotherapy remains individualized and should take into account your complete medical history, pathology, previous treatments, and other factors.
What Does a Negative ctDNA Test Mean?
A negative ctDNA result means that tumor-associated DNA was not detected in the blood sample at that particular time. A negative result may be associated with a lower risk of recurrence compared with a positive result. However, a negative ctDNA test does not mean that the bladder cancer will not return.
Cancer cells may be present at levels below what a test can detect. For this reason, patients who have a negative ctDNA result still need the follow-up appointments, lab tests, physical examinations, imaging, and other surveillance recommended by their care team.
Depending on your situation, your oncologist may also recommend repeated ctDNA testing to look for changes over time.
Does ctDNA Testing Replace Regular Bladder Cancer Surveillance?
No, ctDNA is an additional tool that does not replace standard follow-up care for bladder cancer. Depending on your diagnosis and treatment, your ongoing care may include:
- Imaging studies
- Regular oncology appointments
- Physical examinations
- Laboratory testing
- Other surveillance recommended by your cancer care team
Your oncologist will consider ctDNA results alongside these other sources of information when developing your personalized treatment and surveillance plan. Be sure you attend any follow-up oncology appointments so you can be carefully monitored for recurrent bladder cancer.
Talk to Your Oncologist About ctDNA Testing
If you were diagnosed with muscle-invasive bladder cancer and have undergone, or are preparing for, a radical cystectomy, ask your RMCC cancer care team whether ctDNA testing may be appropriate for you.
Questions you may want to ask include:
- Am I a candidate for ctDNA testing?
- When should ctDNA testing be performed?
- What would a positive result mean for me?
- What would a negative result mean?
- Could my results change my treatment plan?
- Would I need ctDNA testing more than once?
At Rocky Mountain Cancer Centers, our cancer specialists are committed to delivering personalized care using the latest advances in cancer research and treatment. Our team works together to support you at each phase of your cancer journey.
If you or a loved one has been diagnosed with muscle-invasive bladder cancer, talk with an RMCC bladder cancer specialist about your treatment options and whether ctDNA testing may be part of your post-surgical care.